Bharat Immunologicals Intrinsic Value
Bharat Immunologicals (BIBCL) median intrinsic value is ₹23.75 from 3 valuation models (range ₹4–₹35), vs current price ₹14.16 — +67.7% upside (Trading Below Calculated Value), margin of safety 40.4%. See BIBCL P/B ratio to compare market price against book value per share.
BIBCL Valuation Methods Summary — DCF, Graham Number & P/E
Bharat Immunologicals intrinsic value across 3 models vs current price ₹14.16 — upside/downside and value range per method. For current market price and key ratios, visit Bharat Immunologicals stock price NSE.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹35.40 | ₹31.86 - ₹38.94 | +150.0% | Book Value/Share: ₹20.47, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹4.25 | ₹3.83 - ₹4.68 | -70.0% | Revenue/Share: ₹2.09, P/S: 2.0x |
| Simple DCF (5Y) | dcf | ₹23.75 | ₹19.00 - ₹28.50 | +67.7% | CF Growth: 5.0%, Discount: 15% |
BIBCL Intrinsic Value vs Market Price — All Valuation Models
Bharat Immunologicals fair value range ₹4–₹35 vs current market price ₹14.16 across 3 valuation models. Check Bharat Immunologicals market cap to track the company's total market size over time.
BIBCL Intrinsic Value Analysis — Undervalued or Overvalued?
Bharat Immunologicals median intrinsic value ₹23.75, current price ₹14.16 — Trading Below Calculated Value by 67.7%, margin of safety 40.4%.
What is the intrinsic value of BIBCL?
Based on our comprehensive analysis using 3 different valuation methods, the estimated intrinsic value of Bharat Immunologicals (BIBCL) is ₹23.75 (median value). With the current market price of ₹14.16, this represents a +67.7% variance from our estimated fair value.
The valuation range spans from ₹4.25 to ₹35.40, indicating ₹4.25 - ₹35.40.
Is BIBCL undervalued or overvalued?
Based on our multi-method analysis, Bharat Immunologicals (BIBCL) appears to be trading below calculated value by approximately 67.7%.
BIBCL Financial Health — Key Ratios vs Industry Benchmarks
Bharat Immunologicals financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 5.50 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | -20.5% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | -13.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.05x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
BIBCL Cash Flow Quality — Operating & Free Cash Flow
Bharat Immunologicals operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2023 | ₹11 Cr | ₹11 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹-42 Cr | ₹-42 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹12 Cr | ₹12 Cr | Positive Free Cash Flow | 8/10 |
| March 2020 | ₹34 Cr | ₹34 Cr | Positive Free Cash Flow | 8/10 |
| March 2019 | ₹-32 Cr | ₹-32 Cr | Negative Cash Flow | 3/10 |